Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 5/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
| ▸ | TEK | Q02763 | 6/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | FLT1 | P17948 | 4/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FRK | P42685 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22633809 | 0.86 | NPC1 (0.57) | NR1I3RPS6KA3CHEK2TEKKDR | |
| SCHEMBL4769730 | 0.86 | NR1I3 (0.55) | NR1I3RPS6KA3CHEK2TEKFLT1 | |
| SCHEMBL4771935 | 0.86 | TEK (0.59) | NR1I3RPS6KA3CHEK2TEKKDR | |
| SCHEMBL4767114 | 0.85 | TEK (0.60) | NR1I3TEKKDRFLT1PTGS2 | |
| SCHEMBL13387977 | 0.82 | NPC1 (0.60) | NR1I3RPS6KA3CHEK2TEKKDR | |
| SCHEMBL22633832 | 0.82 | NR1I3 (0.54) | NR1I3RPS6KA3CHEK2TEKKDR | |
| SCHEMBL22633918 | 0.82 | NR1I3 (0.54) | NR1I3RPS6KA3CHEK2TEKKDR | |
| SCHEMBL22633836 | 0.82 | NR1I3 (0.54) | NR1I3RPS6KA3CHEK2TEKKDR | |
| SCHEMBL22633824 | 0.80 | NR1I3 (0.55) | NR1I3RPS6KA3CHEK2TEKKDR | |
| SCHEMBL3644258 | 0.77 | PRKD3 (0.42) | NR1I3RPS6KA3CHEK2PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-12 | — | — | US | disclosed |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-12 | — | — | US | disclosed |
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
| EP-1575963-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058776-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | NR1I3 532/4885RPS6KA3 3707/4885CHEK2 1146/4885 |
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | NR1I3 2203/4885RPS6KA3 1401/4885CHEK2 957/4885 |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | CYP2A6, CYP2B6, CYP4A11 | NR1I3 532/4885RPS6KA3 3707/4885CHEK2 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.